<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Although <z:chebi fb="0" ids="17431">agmatine</z:chebi> therapy in a mouse model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> is highly protective against neurological injury, the mechanisms underlying the protective effects of <z:chebi fb="0" ids="17431">agmatine</z:chebi> are not fully elucidated </plain></SENT>
<SENT sid="1" pm="."><plain>This study aimed to investigate the effects of <z:chebi fb="0" ids="17431">agmatine</z:chebi> on brain <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:mp ids='MP_0003354'>astrogliosis</z:mp> and <z:hpo ids='HP_0000969'>edema</z:hpo> in the rats with transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Following surgical induction of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) for 90 min, <z:chebi fb="0" ids="17431">agmatine</z:chebi> (100 mg/kg, i.p.) was injected 5 min after beginning of reperfusion and again once daily for the next 3 post-operative days </plain></SENT>
<SENT sid="3" pm="."><plain>Four days after reperfusion, both motor and proprioception functions were assessed and then <z:hpo ids='HP_0000001'>all</z:hpo> rats were sacrificed for determination of brain <z:mpath ids='MPATH_124'>infarct</z:mpath> volume (2, 3, 5-triphenyltetrazolium <z:chebi fb="76" ids="17996">chloride</z:chebi> staining), <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (TUNEL staining), <z:hpo ids='HP_0000969'>edema</z:hpo> (both cerebral water content and amounts of aquaporin-4 positive cells), <z:hpo ids='HP_0002171'>gliosis</z:hpo> (glial fibrillary acidic protein [GFAP]-positive cells), and neurotoxicity (inducible nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase [iNOS] expression) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The results showed that <z:chebi fb="0" ids="17431">agmatine</z:chebi> treatment was found to accelerate recovery of motor (from 55 degrees to 62 degrees) and proprioception (from 54% maximal possible effect to 10% maximal possible effect) deficits and to prevent <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> (from 370 mm3 to 50 mm3), <z:hpo ids='HP_0002171'>gliosis</z:hpo> (from 80 GFAP-positive cells to 30 GFAP-positive cells), <z:hpo ids='HP_0000969'>edema</z:hpo> (cerebral water contents decreased from 82.5% to 79.4%; AQP4 positive cells decreased from 140 to 84 per section), <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (neuronal apoptotic cells decreased from 100 to 20 per section), and neurotoxicity (iNOS expression cells decreased from 64 to 7 per section) during MCAO ischemic injury in rats </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSIONS: The data suggest that <z:chebi fb="0" ids="17431">agmatine</z:chebi> may improve outcomes of transient <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in rats by reducing brain <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, <z:mp ids='MP_0003354'>astrogliosis</z:mp> and <z:hpo ids='HP_0000969'>edema</z:hpo> </plain></SENT>
</text></document>